CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy

Tumor vaccines trigger tumor-specific immune responses to prevent or treat tumors by activating the hosts’ immune systems, and therefore, these vaccines have potential clinical applications. However, the low immunogenicity of the tumor antigen itself and the low efficiency of the vaccine delivery sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shengyang, Wu, Jiayan, Feng, Yuanji, Guo, Xiaoya, Li, Tong, Meng, Meng, Chen, Jie, Chen, Daquan, Tian, Huayu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535270/
https://www.ncbi.nlm.nih.gov/pubmed/36246666
http://dx.doi.org/10.1016/j.bioactmat.2022.09.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535270/
https://www.ncbi.nlm.nih.gov/pubmed/36246666
http://dx.doi.org/10.1016/j.bioactmat.2022.09.017

Ejemplares similares